摘要
目的:探讨纤溶酶原激酶衍生物应用于急性心肌梗死(AMI)患者治疗中的疗效。方法:收治AMI患者88例,随机分为试验组和对照组,各44例。对照组使用尿激酶治疗,试验组使用重组人组织型纤溶酶原激酶衍生物治疗,比较24 h冠脉再通率、 NT-ProBNP水平。结果:试验组24 h冠脉再通率显著较对照组高,NT-ProBNP水平显著较对照组低(P<0.05)。结论:重组人组织型纤溶酶原激酶衍生物可有效改善AMI患者预后,提高24 h冠脉再通率。
Objective：To investigate the efficacy of plasminogen kinase derivatives in the treatment of AMI patients.Methods：88 patients with AMI were selected,they were randomly divided into the experimental group and the control group with 44 eases in each group.The control group was treated with urokinase,and the experimental group was treated with recombinant human tissue plasminogen kinase derivatives.The eoronary reeanalization rate and NT-ProBNP level were compared at 24h.Resuhs：The 24h eoronary reeanalization rate of the experimental group was significantly higher than that of the control group,and the NT-ProBNP level was significantly lower than that of the control group（P 〈 0.05）.Conclusion：Recombinant human tissue-type plasminogen kinase derivalives can improve the prognosis of patients with AMI and improve coronary recanalization rate at 24h effectively.
作者
张习敬
Zhang Xijing(Department of Cardiology,General Hospital of Pan Jiang Investment Holdings（Group）Co.,Ltd.,Guizhou,Liupanshui 55353)
出处
《中国社区医师》
2018年第33期90-90,92,共2页
Chinese Community Doctors
